Syros Pharmaceuticals, Inc. (SYRS) financial statements (2021 and earlier)

Company profile

Business Address 35 CAMBRIDGE PARK DRIVE
CAMBRIDGE, MA 02140
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:174911007284
Cash and cash equivalents17441503259
Short-term investments 50504025
Other undisclosed cash, cash equivalents, and short-term investments0(0)0  
Restricted cash and investments 010 
Receivables0   1
Contract with customer, asset2  
Other undisclosed current assets223111
Total current assets:1791151027386
Noncurrent Assets
Finance lease, right-of-use asset11
Operating lease, right-of-use asset1516
Property, plant and equipment1415445
Restricted cash and investments33000
Other noncurrent assets20110
Total noncurrent assets:3535556
TOTAL ASSETS:2131501077891
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1011765
Accounts payable46322
Accrued liabilities11111
Employee-related liabilities64322
Deferred revenue126
Debt01000
Deferred compensation liability    0
Deferred revenue and credits 1
Contract with customer, liability2
Other undisclosed current liabilities661164
Total current liabilities:2924201210
Noncurrent Liabilities
Long-term debt and lease obligation6424000
Long-term debt, excluding current maturities40    
Finance lease, liability0 
Capital lease obligations000
Operating lease, liability2524
Liabilities, other than long-term debt1023811
Deferred revenue and credits11
Deferred revenue1023
Contract with customer, liability8
Total noncurrent liabilities:7447811
Total liabilities:10370281311
Stockholders' equity
Stockholders' equity attributable to parent9179796581
Common stock00000
Additional paid in capital468372296221182
Accumulated other comprehensive income (loss) 0(0)(0)(0)
Accumulated deficit(377)(293)(218)(155)(101)
Total stockholders' equity:9179796581
Other undisclosed liabilities and equity2010  
TOTAL LIABILITIES AND EQUITY:2131501077891

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net10
Gross profit:152210
Operating expenses(97)(80)(66)(56)(48)
Operating loss:(82)(78)(64)(55)(48)
Nonoperating income02210
Investment income, nonoperating0    
Other nonoperating income 2210
Interest and debt expense(2)(0)   
Loss from continuing operations before income taxes:(84)(76)(62)(54)(48)
Income tax expense(0)(0)(0)  
Loss before gain (loss) on sale of properties:(84)(76)(62)(54)(48)
Other undisclosed net income (loss)(0)00  
Net loss attributable to parent:(84)(75)(62)(54)(48)
Preferred stock dividends and other adjustments    (4)
Net loss available to common stockholders, diluted:(84)(75)(62)(54)(51)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(84)(75)(62)(54)(48)
Other comprehensive loss    (48)
Comprehensive loss:(84)(75)(62)(54)(95)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)00(0) 
Comprehensive loss, net of tax, attributable to parent:(84)(75)(62)(54)(95)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: